Details for Patent: 11,179,434
✉ Email this page to a colleague
Which drugs does patent 11,179,434 protect, and when does it expire?
Patent 11,179,434 protects QBRELIS and is included in one NDA.
This patent has ten patent family members in eight countries.
Drugs Protected by US Patent 11,179,434
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | 11,179,434 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,179,434
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 3003274 | ⤷ Subscribe | |||
China | 108472252 | ⤷ Subscribe | |||
China | 112972370 | ⤷ Subscribe | |||
European Patent Office | 3368012 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |